Hannah Hildebrand

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma

Ambreen Muhammed, Claudia Angela Maria Fulgenzi, Sirish Dharmapuri et al. · Cancers · 2021 · 82 citations · Full text

Medicine, Immunology, Oncology +17

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

David J. Pinato, Takahiro Kaneko, Anwaar Saeed et al. · Cancers · 2020 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study

Brett Marinelli, Edward Kim, Antonio D’Alessio et al. · Journal for ImmunoTherapy of Cancer · 2022 · 73 citations · Full text

Medicine, Oncology, Pharmacology +17

Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice

David J. Pinato, Thomas U. Marron, Pallavi S. Mishra‐Kalyani et al. · European Journal of Cancer · 2021 · 64 citations

Medicine, Immunology, Oncology +17